Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system.

ABSTRACT: Background: COVID-19 patients with underlying medical conditions are vulnerable to drug-drug interactions (DDI) due to the use of multiple medications. We conducted a discovery-driven data analysis to identify potential DDIs and associated adverse events (AEs) in COVID-19 patients from the FDA Adverse Event Reporting System (FAERS), a source of post-market drug safety. Materials and Methods: We investigated 18,589 COVID-19 AEs reported in the FAERS database between 2020 and 2021. We applied multivariate logistic regression to account for potential confounding factors, including age, gender, and the number of unique drug exposures. The significance of the DDIs was determined using both additive and multiplicative measures of interaction. We compared our findings with the Liver

SUBMITTER: Jeong E 

PROVIDER: S-EPMC9353301 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature